Table 4.
Therapeutic areas targeted by innovative antibodies, Fc fusion proteins, and CARs in clinical development*
| Therapeutic area | Major indications for antibodies in phase of development | Totals | ||
|---|---|---|---|---|
| Phases I and II | Phase III | Marketed | ||
| Oncology (antibodies and Fc fusion proteins) | 346 | 30 | 33 | 409 (46%) |
| Oncology (CAR-T and CAR-NK clinical candidates incorporating antibodies) | 145 | 0 | 0 | 145 (16%) |
| Inflammation and autoimmune diseases | 132 | 15 | 25 | 172 (19%) |
| Ophthalmology | 16 | 2 | 2 | 20 (2.3%) |
| Infectious diseases | 28 | 6 | 4 | 38 (4.3%) |
| Neurobiology diseases | 20 | 3 | 3 | 26 (2.9%) |
| Cardiovascular and metabolic diseases | 23 | 0 | 5 | 28 (3.2%) |
| Blood diseases | 12 | 5 | 4 | 21 (2.4%) |
| Pain | 3 | 6 | 0 | 9 (1.0%) |
| Bone and muscle diseases | 7 | 4 | 2 | 13 (1.5%) |
| Other or not disclosed | 2 | 1 | 0 | 3 (na) |
| Total number of uses in each therapeutic area | 734 | 72 | 78 (all are mAbs/Fc fusion proteins) | 884 total uses in therapeutic areas |
| Total number of unique targets (all therapeutic areas) | -- | -- | -- | 328 unique targets |
| Number of programs per target | -- | -- | -- | Average ~2.7 clinical programs/target |
Abbreviations: CAR, chimeric antigen receptor; NK, natural killer; mAbs, monoclonal antibodies; Fc, fragment, crystallizable
* Database lock for these data was April 30, 2017; BiStro Biotech Consulting LLC database. The total number of therapeutic area indications is greater than the number of molecules because some targeted antibodies have been used widely in different indications (e.g., anti-vascular endothelial growth factor [VEGF] antibodies used in both oncology and ophthalmology indications)